Skip to content

Continuous Erector Spinae Block Versus Continuous Paravertebral Block

Continuous Erector Spinae Block Versus Continuous Paravertebral Block Following Thoracotomy: A Randomized, Controlled Non-Inferiority Study

Status
Terminated
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03768440
Enrollment
34
Registered
2018-12-07
Start date
2019-04-16
Completion date
2025-02-01
Last updated
2026-05-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pain, Postoperative

Keywords

ropivacaine infusion, regional anesthesia, paravertebral block, erector spinae block

Brief summary

Overall Aim: To evaluate the efficacy of continuous erector spinae block (ESB) versus continuous paravertebral block (PVB) for postoperative analgesia in children and adolescents undergoing surgical procedures via unilateral thoracotomy. Hypothesis: The investigators hypothesize that ESP block efficacy is not inferior to that of PVB with respect to pain control and consumed opiate equivalents at 24 hours postoperatively.

Detailed description

Regional anesthesia-and pediatric regional anesthesia in particular-is a rapidly evolving subfield of anesthesia practice driven with considerable urgency by the growing recognition that even appropriate perioperative narcotic administration can have significant derogatory long-term effects. Regional anesthetics can provide targeted, continuous analgesia to select dermatomes with minimal additional patient risk and have become routine components of opioid-sparing intraoperative and postoperative pain management plans for surgical patients at BCH. In addition to the postulated benefit of reducing overall opioid exposure and potentially reducing the risk for long term physiologic and behavioral dependence upon opioids, regional anesthetics may allow for earlier extubation after selected surgeries, shorter ICU, PACU and inpatient admissions, earlier mobilization, fewer gastrointestinal complications, and improved patient satisfaction scores. Given the rapid evolution of the field of regional anesthesia and the fact that there are often multiple approaches for achieving analgesia in a select set of dermatomes, there are often a variety of regional anesthetic options for any given surgery. Some approaches are longstanding and well-studied, but with increasing frequency since the advent of ultrasound guidance, newer, novel nerve block options exist. As it is often expensive and work-intensive to thoroughly evaluate a given regional technique with a controlled pediatric trial, many of these blocks become standards of practice based on anecdote, retrospective analysis, or simply belief in the putative benefits of regional anesthetics. The investigators are fortunate at BCH to have one of the largest concentrated pediatric surgical populations in the US. They also have an active, and well organized regional anesthesia service. Because of this, the investigators are in a unique position to more thoroughly evaluate the effectiveness and safety of regional anesthesia in children. Furthermore, the investigators feel it is critical that institutions such as BCH take a leading role in documenting the effects of regional anesthesia on the most important outcome measures when considering perioperative medicine. These include overall pain management, surgical healing, functional recovery, long-term pain symptoms, and emotional/behavioral outcomes after surgery. Recently the ESB has become popular for providing analgesia after a number of anterior chest and abdominal procedures. This is a simple interfascial plane block that can reliably provide unilateral chest and/or abdominal wall analgesia. It has been described in numerous case reports and one case series as an effective block for management of unilateral thoracotomies, unilateral rib fractures, unilateral abdominal incisions and (when used bilaterally) for management of post-sternotomy pain. As an interfascial plane block in a compressible anatomical space, the ESB is thought to be safe in anticoagulated (or recently anticoagulated) patients. It is fast becoming a preferred anesthetic option for these patients as opposed to neuraxial (e.g. epidural) and paraneuraxial (i.e. paravertebral) nerve blocks. Given the ESB's potentially favorable risk profile versus the other blocks (it is technically less challenging, more distant from critical structures, and thought to be safe in anticoagulated patients) it could provide both a safer and easier to perform regional anesthesia option for many patients. It also offers a new option for a subset of anticoagulated patients for whom other regional techniques (epidural, paravertebral) are contraindicated. Indeed, given the current information available related to the ESB, the regional anesthesia service at BCH has begun employing it when possible in circumstances where a PVB would commonly be used but is relatively or absolutely contraindicated. Patients undergoing thoracotomies while anticoagulated for cardiopulmonary bypass, aortic clamping, etc. have been successfully managed with continuous ESBs. In addition, thoracotomies in patients with acquired (e.g. dilutional) and other pathologic coagulopathies have been managed with ESBs. As such, the ESB has been adopted for routine use in specific patient populations at BCH and has even occasionally been utilized in lieu of the more longstanding routine PVBs or epidural blocks for patients without contraindication for such. Retrospective review of BCH outcomes data for 47 ESBs done for a variety of surgeries and populations has not revealed any significant differences between PVBs and ESBs in terms of adverse events, postoperative opiate use, median pain scores, or other standard outcomes measures. As this data is observational in nature, it is difficult to draw firm conclusions as to the comparative efficacy of the two blocks. However, since there are differences in technical difficulty, relative contraindications, and there exist populations that might benefit from these blocks, it would be prudent to comparatively evaluate these blocks in a controlled, randomized, trial. The investigators propose to evaluate the comparative efficacy of ESBs and PVBs for patients undergoing unilateral non-cardiac thoracotomy by means of a randomized, controlled non-inferiority study (based on a threshold of clinical significance being defined as a 15% difference) comparing rescue analgesic requirements, rendered as opiate equivalents, at 24 postoperatively. Rescue opiates will be available as needed by means of standard PCA/NCA demand protocols. Secondary measures will include rescue opiate requirements at 48 and 72 hours, pain scores, adverse events, time to discharge from the ICU, time to extubation, patient disposition after surgery, and time to perform the block in the operating room.

Interventions

PROCEDUREcontinuous erector spinae block (ESB)

Erector spinae block: T4/5 transverse process is identified with the ultrasound transducer in a parasagittal orientation; the needle tip is advanced until it contacts the transverse process, just below the erector spinae muscle complex; the erector spinae muscle is visualized to be elevated up off of the transverse process with normal saline injection. Following a bolus injection of 2ml/kg of 0.2% ropivacaine, a catheter is threaded into the space occupied by the local anesthetic bolus.

PROCEDUREcontinuous paravertebral block (PVB)

The paravertebral space (bound medially by the bodies of the vertebrae, intervertebral discs, and intervertebral foraminae; anterolaterally by the parietal pleura and the innermost intercostal membrane; posteriorly by the transverse processes of the thoracic vertebrae, heads of the ribs, and the superior costotransverse ligament) laying between T4/5 is identified using the ultrasound transducer in a transverse orientation; the needle tip is advanced until it is seen passing under the transverse process, immediately superior to the pleura; the pleura is seen to deflect downward with normal saline injection. Following a bolus injection of 2ml/kg of 0.2% ropivacaine, a catheter is threaded into the space occupied by the local anesthetic bolus.

DRUGRopivacaine

Ropivacaine 0.2% will be the drug used for each group (ESB group and PVB group)

Sponsors

Boston Children's Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
1 Months to 12 Years
Healthy volunteers
Yes

Inclusion criteria

* ASA I - III status, undergoing unilateral thoracotomy for either esophageal atresia related intrathoracic procedures or other non-cardiac general surgical intrathoracic procedures.

Exclusion criteria

* Patients undergoing procedures including pleurodesis, pleural stripping, and decortication or other procedures with widely distributed pleural disruption. * Patients with severe neurodevelopmental delays. * Patients with previous chronic pain syndromes. * Patients with a history of opioid treatment at any point in the 2 months prior to surgery. * Lack of parental consent and/or child assent.

Design outcomes

Primary

MeasureTime frameDescription
Rescue Analgesic Consumption24 hoursrescue opiates (rendered as morphine equivalents/kg) given by blinded providers using standard PCA/NCA demand protocols

Countries

United States

Contacts

PRINCIPAL_INVESTIGATORROLAND BRUSSEAU, MD

Boston Children's Hospital

Baseline characteristics

Characteristic
Age, Continuous2.88 years
Race and Ethnicity Not Collected0 Participants
Sex: Female, Male
Female
3 Participants
Sex: Female, Male
Male
25 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
0 / 160 / 18
other
Total, other adverse events
0 / 160 / 18
serious
Total, serious adverse events
0 / 160 / 18

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: May 14, 2026